banda transcan 2 2016ul

Title: An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology determinants.


Project Coordinator:
Zdenko HERCEG (France) International Agency for Research on Cancer (IARC), Lyon


Project Partners:
Christoph BOCK (Austria) CeMM Research Center for Molecular Medicine, Vienna
Suzette DELALOGE (France) Institut Gustave Roussy, Villejuif
Rudolf KAAKS (Germany) German Cancer Research Center (DKFZ), Heidelberg
Vessela KRISTENSEN (Norway) University of Oslo, Oslo
Christoph PLASS (Germany) German Cancer Research Center (DKFZ), Heidelberg
Wim VAN CRIEKINGE (Belgium) University of Ghent, Ghent


Project Abstract:
Despite the availability of new chemotherapeutic agents and progress in screening, breast cancer is still the most common cancer affecting women in developed countries. Epigenetic changes are ubiquitous in primary breast cancer, but less is known about the dietary/lifestyle and endogenous determinants of these changes. This project’s underlying hypothesis is that environmental factors and endogenous cues trigger changes in the methylome, that these changes contribute to the onset of breast cancer, and that they can serve as biomarkers in primary and secondary prevention. The project’s three main objectives are: (1) to identify DNA methylome changes in breast cancer and surrogate tissue using a large sample of several thousand subjects from a prospective cohort, (2) to establish dietary/lifestyle and endogenous determinants of epigenetic changes, and (3) to assess the predictive value of methylation markers in clinical settings. This project is based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, a study conducted in 23 centres in 10 European countries, and will use powerful epigenomic technology for biomarker discovery and validation. This study will provide unique insights into the role of risk factors in driving the epigenetic changes that are associated with breast cancer, and will reveal potential targets for biomarker discovery and future preventative strategies. Thus, the proposal is highly relevant to the main objectives of this call: providing a scientific basis for primary and secondary prevention of cancer.

(Project funded under JTC 2012)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 25 guests and no members online